FREMONT, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Vermillion, Inc. (VRML) announced that on December 3, 2009, it filed its First Amended Plan of Reorganization and related amended Disclosure Statement with the United States Bankruptcy Court for the District of Delaware.
"We are pleased to report that we have continued cooperation from our stakeholders on the restructuring," said Gail Page, Vermillion Executive Chairperson. "We have also made significant progress improving our balance sheet by equitizing most of our convertible debt. The principal balance of our 7% Senior Convertible Notes due 2011 has now been reduced to $5 million."
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at www.vermillion.com.
OVA1(TM) Test is a trademark of Vermillion Inc.
Vermillion, Inc.
